Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network
Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network
复制标题
DOI：
10.1002/pros.20381
复制
发表时间：
2006-05-01
期刊：
影响因子：
2.8
通讯作者：
Jung, K
中科院分区：
文献类型：
--
作者：
Stephan, C;Xu, CL;Jung, K
背景。我们的目的是评估巨噬细胞抑制细胞因子 1 (MIC1)、人激肽释放酶 11 (hK11) 迁移抑制因子 (MIF) 与前列腺特异性抗原 (PSA) 和 %fPSA 相比的价值，并开发基于 %fPSA 的 ANN，并使用新的输入因子来确定这些附加标记是否可以进一步消除不必要的前列腺活检。方法。对 371 名 PSA 范围为 0.5-20 μg/L 的前列腺癌 (PCa，n = 135) 或良性前列腺增生 (BPH，n = 236) 患者的血清样本进行了总 PSA、游离 PSA、MIC-1、hK11 和 MIF 的分析。构建了具有这些变量和前列腺体积的“留一”ANN 模型，并与逻辑回归 (LR) 和所有单一参数进行比较。结果。尽管 BPH 与 PCa 患者存在显着差异，但 MICA、hK11 和 MIF 的辨别能力小于 PSA。在 90% 和 95% 的灵敏度下，如果包括前列腺体积，人工神经网络 (ANN) 仅显着优于 %fPSA。结论。与 %fPSA 和 tPSA 相比，具有 MICA、MIF 和/或 hK11 新颖输入因子以及额外使用前列腺体积的 ANN 表现出显着优势，并可能减少不必要的前列腺活检。
BACKGROUND. We aimed to evaluate the value of macrophage inhibitory cytokine 1 (MIC1), human kallikrein 11 (hK11) migration inhibitor factor (MIF) in comparison to prostate-specific antigen (PSA) and %fPSA and also to develop a %fPSA-based ANN with the new input factors to determine whether these additional markers can further eliminate unnecessary prostate biopsies.METHODS. Serum samples from 371 patients with prostate cancer (PCa, n = 135) or benign prostate hyperplasia (BPH, n = 236) within the PSA range 0.5-20 mu g/L were analyzed for total PSA, free PSA, MIC-1, hK11, and MIF. 'Leave one out' ANN models with these variables and prostate volume were constructed and compared to logistic regression (LR) and all single parameters.RESULTS. The discriminatory power of MICA, hK11, and MIF was less than that for PSA despite significant differences in BPH compared to PCa patients. At 90% and 95% sensitivity, the artificial neural networks (ANNs) were only significantly better than %fPSA if prostate volume was included.CONCLUSIONS. ANNs with the novel input factors of MICA, MIF, and/or hK11 and additional use of prostate volume demonstrated significant advantage compared with %fPSA and tPSA and may lead to a reduction in unnecessary prostate biopsies.